RESUMO
Appropriate tools are necessary for predicting cardiovascular events in patients with diabetes mellitus because of their high incidence. In this study, we assessed whether a combination of brain natriuretic peptide (BNP) and C-reactive protein (CRP) measurement were useful prognosticators in patients with type 2 diabetes mellitus. One hundred and nine patients with type 2 diabetes mellitus, aged 52 to 93 years, were examined at outpatient clinics for blood, urinary samples, and echocardiography. They were then followed prospectively. During the average follow-up period of 30 months (range, 3 to 37), 15 patients (14%) had cardiovascular events: This was the first event in 5 patients and a recurrence in 10. Cox regression analysis showed that the past event (hazard ratio [HR] 4.819 [95% confidence interval (CI): 1.299-17.881]; p = 0.019) and plasma BNP level (HR 1.007 [95% CI: 1.002-1.012]; p = 0.010] were independently significant factors for the cardiovascular events during the follow-up period. Patients with plasma BNP > or =53 pg/mL and CRP > or =0.95 mg/dL demonstrated the highest incidence in cardiovascular event, compared to those categorized into either or both low levels of BNP and CRP. This study suggests that combination of plasma BNP and CRP measurement provides the additive prognostic information of cardiovascular events in patients with type 2 diabetes mellitus.
Assuntos
Proteína C-Reativa/análise , Doenças Cardiovasculares/sangue , Diabetes Mellitus Tipo 2/sangue , Peptídeo Natriurético Encefálico/sangue , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Doenças Cardiovasculares/diagnóstico por imagem , Doenças Cardiovasculares/prevenção & controle , Métodos Epidemiológicos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pacientes Ambulatoriais , Prognóstico , Medição de Risco , Ultrassonografia Doppler em CoresRESUMO
Both adrenomedullin (AM) and angiotensin II (Ang II) are locally-acting hormones in the cardiac ventricles. Previously we reported that AM inhibits Ang II-induced hypertrophy of cultured rat neonatal cardiomyocytes. In this study, we examined whether Ang II affects the gene expression of the AM receptor components of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP) in rat cardiomyocytes. The mRNA levels of RAMP1 and RAMP3 were significantly elevated following 24-h treatment with Ang II without a change of those of RAMP2 and CRLR. AM increased the intracellular cAMP level and the cAMP accumulation by AM was significantly amplified by the 24-h preincubation with Ang II. The effects of Ang II on RAMP1 and RAMP3 expression were abolished by an Ang II type 1 (AT1) receptor antagonist, but not by an AT2 receptor antagonist. Thus, Ang II modulates gene expression of the AM receptor components via AT1 receptor, suggesting alteration of AM actions by Ang II in cultured rat cardiomyocytes.
Assuntos
Angiotensina II/farmacologia , Expressão Gênica/efeitos dos fármacos , Proteínas de Membrana/metabolismo , Miócitos Cardíacos/efeitos dos fármacos , Receptores da Calcitonina/metabolismo , Receptores de Peptídeos/metabolismo , Angiotensina II/antagonistas & inibidores , Antagonistas de Receptores de Angiotensina , Animais , Animais Recém-Nascidos , Proteína Semelhante a Receptor de Calcitonina , Células Cultivadas , AMP Cíclico/genética , AMP Cíclico/metabolismo , Peptídeos e Proteínas de Sinalização Intracelular , Proteínas de Membrana/genética , Miócitos Cardíacos/metabolismo , RNA Mensageiro/metabolismo , Ratos , Ratos Wistar , Proteína 1 Modificadora da Atividade de Receptores , Proteína 2 Modificadora da Atividade de Receptores , Proteína 3 Modificadora da Atividade de Receptores , Proteínas Modificadoras da Atividade de Receptores , Receptor Tipo 1 de Angiotensina , Receptores de Adrenomedulina , Receptores da Calcitonina/genética , Receptores de Peptídeos/genética , Reação em Cadeia da Polimerase Via Transcriptase ReversaRESUMO
PURPOSE: To evaluate the results and significance of radiotherapy for carcinoma involving the external auditory canal or middle ear. MATERIALS AND METHODS: Six patients underwent radiotherapy. Five patients had squamous cell carcinoma and one had ceruminous adenocarcinoma. In addition to radiotherapy, two patients underwent complete resection, and the other patient underwent incomplete resection. Total radiation doses ranged from 30 to 88 Gy (2 Gy/fraction, 5 fractions/week). RESULTS: The post-treatment survival period ranged from 8 months to 7 years (mean, 3 years, 11 months). Two patients treated by radiotherapy alone (doses of more than 60 Gy) lived for more than five years. CONCLUSION: The prognosis of patients with advanced cancer involving the external auditory canal and middle ear is generally poor. Based on even this limited clinical experience, a tumor dose of at least 70 Gy should be delivered for local control of advanced cancer. To avoid complications, several plans such as application of the shrinking field technique are recommended.
Assuntos
Adenocarcinoma/radioterapia , Carcinoma de Células Escamosas/radioterapia , Meato Acústico Externo , Neoplasias da Orelha/radioterapia , Orelha Média , Idoso , Intervalo Livre de Doença , Fracionamento da Dose de Radiação , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Dosagem Radioterapêutica , Fatores de Tempo , Resultado do TratamentoRESUMO
A 67-year-old female non-smoker, who had been diagnosed with familial hypercholesterolemia associated with severe atherosclerosis of the coronary, carotid and vertebral arteries, developed interstitial pneumonia 4 months after initiating ticlopidine to inhibit platelet aggregation. The lymphocyte stimulation test by ticlopidine was positive and bronchoalveolar lavage fluid showed an increase in lymphocytes and a decrease in the CD4+/8+ ratio, suggesting potentially undesirable side effects of ticlopidine. Two months after ticlopidine therapy was discontinued and prednisolone therapy started, the interstitial pneumonia had almost completely resolved. Two patients, one with ticlopidine-associated bronchiolitis obliterans organizing pneumonia and the other with pneumonia with multiple nodules, have been reported to date and the present patient is the third reported case of ticlopidine-induced pneumonia. The incidence of this side effect may not be so high because approximately 20 years have passed since ticlopidine was first marketed in Japan, but because the drug is now widely prescribed, this serious clinical side effect should be considered.